Good pickup. It is interesting that the market release doesn't provide the same detail as PAA has provided. At a glance,our survival rate is better. Although stating significant slowing of disease progression via ALSFRS scores, it doesn't provide actual figures. Will enter phase 3 study next year but appears to be about a year behind PAA.
Pharmaust - Media & News, page-89
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.015(6.98%) |
Mkt cap ! $111.9M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 23.0¢ | 21.5¢ | $475.3K | 2.128M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 93524 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 71004 | 2 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |